Dee van der Knaap

Dee van der Knaap is an accomplished investment professional with extensive experience in private credit strategies and life sciences. Currently at Blackstone since November 2024, Dee focuses on investment opportunities in Blackstone Private Credit Strategies and Blackstone Life Sciences. Prior experience includes serving as an investment professional at Petrichor, specializing in venture, growth, and structured equity/credit investing in therapeutics and life sciences from June 2022 to September 2024. Dee also contributed to corporate strategy and business development at Entrada Therapeutics, with a focus on capital raising and strategic partnerships between February 2021 and June 2022. Earlier in their career, Dee worked in equity research at Bank of America Merrill Lynch, analyzing healthcare, life sciences, and diagnostics as part of a top-ranked team from July 2018 to October 2020. Dee holds a Master of Science in Experimental and Translational Therapeutics from the University of Oxford and a Bachelor’s degree in Psychology and Neuroscience, graduating Cum Laude from Wellesley College.